

EMSELLA®

Urinary Incontinence Clinical Outcomes Overview

Urinary Incontinence

72%

Improvement in
UI at 6 months⁷

95%

Of Patients Had an
Improvement in
Quality of Life⁴

64%

Improvement
in Nocturia¹

57%

Average Hygiene Pad
Reduction²

100%

of patients had improved
awareness of their pelvic
floor muscles⁴

53%

Improvement in
sleep & energy⁶

42%

Improvement in patients
ability to fully empty their
bladder⁵

Other Outcomes

7x

More Effective Compared
to Pelvic Floor Muscle
Training²

3x

More Effective Compared to
Electrical Stimulation³

FDA Clearance: BTL EMSSELLA is intended to provide entirely non-invasive electromagnetic stimulation of pelvic floor musculature for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.

Health Canada License: BTL EMSSELLA is a non-invasive therapeutic device intended for stimulation of neuromuscular tissue. The neuromuscular stimulation results in pelvic floor muscle strengthening for treatment of urinary incontinence. BTL EMSSELLA can be used to improve sexual satisfaction of patients who experience somatic sexual arousal disorder symptoms triggered by weak pelvic floor muscles.

References:

- 1) Samuels et al., 2019, DOI:10.1002/ism.23106
- 2) Guerette et al., 2023, DOI: 10.35248/2167-0420.23.12.680,
- 3) Silantyeva et al., 2019, DOI: 10.1097/SPV.0000000000000807
- 4) Berenholz, J., Sims, T., & Botros, G. HIFEM technology can improve quality of life of incontinent patients. Liverpool, UK.
- 5) Singhal & Gopal, 2023, DOI:10.35248/2167-0420.23.12.701
- 6) Azparren & Brandeis, 2024, DOI: 10.35248/2168-9857.24.13.340
- 7) Evans et al., 2023, DOI: 10.35248/2167-0420.23.12.625